Edition:
United States

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

3,849JPY
17 May 2019
Change (% chg)

¥-2 (-0.05%)
Prev Close
¥3,851
Open
¥3,844
Day's High
¥3,903
Day's Low
¥3,790
Volume
8,225,100
Avg. Vol
8,904,243
52-wk High
¥4,943
52-wk Low
¥3,498

About

Takeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Ethical Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, anticancer drugs, drugs for central neurological diseases,... (more)

Overall

Beta: 0.77
Market Cap(Mil.): ¥6,023,708.00
Shares Outstanding(Mil.): 1,565.01
Dividend: 90.00
Yield (%): 4.68

Financials

  4502.T Industry Sector
P/E (TTM): 22.39 54.03 55.51
EPS (TTM): 171.88 -- --
ROI: 1.48 11.89 11.59
ROE: 3.05 13.19 16.33

Japan's Takeda expects binding offers for Latam business by end of May: sources

SAO PAULO Japan's Takeda Pharmaceutical Co expects to receive binding offers for its Latin American business by the end of May, three sources with knowledge of the matter said.

May 16 2019

Japan's Takeda expects binding offers for Latam business by end of May -sources

SAO PAULO, May 16 Japan's Takeda Pharmaceutical Co expects to receive binding offers for its Latin American business by the end of May, three sources with knowledge of the matter said.

May 16 2019

UPDATE 2-Japan's Takeda forecasts surprise annual loss on Shire-related costs

* 193 bln Y op loss forecast this yr vs 227.5 bln profit view of analysts

May 14 2019

Japan's Takeda forecasts 193 billion yen annual operating loss on Shire deal

TOKYO Takeda Pharmaceutical Co forecast on Tuesday it would have an operating loss in the current financial year, as it books costs associated with the multibillion-dollar Shire deal.

May 14 2019

Japan's Takeda expects annual loss on Shire deal

TOKYO, May 14 Takeda Pharmaceutical Co forecast on Tuesday it would have an operating loss in the current financial year, as it books costs associated with the multibillion-dollar Shire deal.

May 14 2019

Deals of the day-Mergers and acquisitions

May 9 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Thursday:

May 09 2019

Novartis buys dry eye drug from Takeda for up to $5.3 billion

TOKYO/ZURICH Novartis is buying dry-eye drug Xiidra from Takeda Pharmaceutical Co for up to $5.3 billion as the Swiss drugmaker refreshes its ophthalmic medicines portfolio with a potential blockbuster.

May 09 2019

UPDATE 3-Novartis buys dry eye drug from Takeda for up to $5.3 bln

* Deal for Shire-developed drug includes 400 Takeda staff (Adds details, comment from analyst)

May 09 2019

Novartis buys Takeda's dry eye drug for $3.4 bln

May 8 Swiss drugmaker Novartis AG said on Wednesday it agreed to acquire Takeda Pharmaceutical Company Ltd's dry eye drug Xiidra for an upfront payment of $3.4 billion to expand its portfolio of eye care medicines.

May 08 2019

BRIEF-Takeda says To Sell Xiidra To Novartis For Up To $5.3 Bln

* TAKEDA SIMPLIFIES PORTFOLIO AND ACCELERATES DELEVERAGING THROUGH TWO DIVESTITURES

May 08 2019

Earnings vs. Estimates